Get startedLog in
    Picture of Notable Labs logo

    NTBLQ — Notable Labs News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro Cap
    All News

    Brief: VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec

    Picture of Notable Labs logoNotable Labs
    26/04/2022 13:06
    April 26 (Reuters) - Vascular Biogenics Ltd  VBLT.O :
    * VBL THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR
OFRA-VEC FOR THE TREATMENT OF PLATINUM-RESISTANT OVARIAN CANCER
    * VBL THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR
OFRA-VEC FOR THE TREATMENT OF PLATINUM-RESISTANT OVARIAN CANCER
    * VBL THERAPEUTICS- OVAL PHASE 3 TOP-LINE PROGRESSION FREE
SURVIVAL (PFS) PRIMARY ENDPOINT DATA FOR OFRA-VEC EXPECTED IN 2H
2022

Source text for Eikon:  ID:nGNX34BfLM 
Further company coverage:  VBLT.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Notable Labs

    See all news